Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TXNRD1 | Q16881 | 17/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | GSR | P00390 | 1/20 | 0.48 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29392101 | 0.92 | TXNRD1 (0.44) | TXNRD1ALDH1A1GSRMAPTMAPK1 | |
| SCHEMBL24251666 | 0.92 | TXNRD1 (0.44) | TXNRD1ALDH1A1GSRMAPTMAPK1 | |
| SCHEMBL30937582 | 0.91 | ALDH1A1 (0.60) | TXNRD1ALDH1A1GSRS1PR4MAPT | |
| SCHEMBL14333655 | 0.88 | ALDH1A1 (0.46) | TXNRD1ALDH1A1GSRMAPTMAPK1 | |
| SCHEMBL20066169 | 0.87 | TXNRD1 (0.49) | TXNRD1ALDH1A1GSRS1PR4MAPT | |
| SCHEMBL26110612 | 0.85 | ALDH1A1 (0.50) | ALDH1A1MAPTMAPK1RAB9A | |
| SCHEMBL30889027 | 0.83 | ALDH1A1 (0.48) | TXNRD1ALDH1A1GSRMAPTMAPK1 | |
| SCHEMBL6642983 | 0.83 | ALDH1A1 (0.48) | TXNRD1ALDH1A1GSRMAPTMAPK1 | |
| SCHEMBL14709951 | 0.81 | TXNRD1 (0.44) | TXNRD1ALDH1A1GSRS1PR4MAPT | |
| SCHEMBL29597784 | 0.79 | ALDH1A1 (0.44) | ALDH1A1MAPTMAPK1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250368647-A1 | NITROGEN CONTAINING CONDENSED 2,3-DIHYDROQUINAZOLINONE COMPOUNDS AS NAV1.8 INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2025-12-04 | — | — | US | disclosed |
| EP-4536660-A1 | NITROGEN CONTAINING CONDENSED 2,3-DIHYDROQUINAZOLINONE COMPOUNDS AS NAV1.8 INHIBITORS | GlaxoSmithKline Intellectual Property Development Ltd (GB) | 2025-04-16 | — | — | EP | disclosed |
| WO-2023238065-A1 | NITROGEN CONTAINING CONDENSED 2,3-DIHYDROQUINAZOLINONE COMPOUNDS AS NAV1.8 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-12-14 | — | — | WO | disclosed |
| CN-109996792-B | Heterocyclic compounds having activity as modulators of muscarinic M1 and/or M4 receptors in the treatment of CNS diseases and pain | 赫普泰雅治疗有限公司 | 2023-02-17 | — | — | CN | disclosed |
| CN-111592541-B | Macrocyclic kinase inhibitors and uses thereof | 山东轩竹医药科技有限公司 | 2021-09-10 | — | — | CN | disclosed |
| CN-111592541-A | Macrocyclic kinase inhibitors and uses thereof | 山东轩竹医药科技有限公司 | 2020-08-28 | — | — | CN | disclosed |
| WO-2018069732-A1 | HETEROCYCLIC COMPOUNDS HAVING ACTIVITY AS MODULATORS OF MUSCARINIC M1 AND/OR M4 RECEPTORS IN THE TREATMENT OF CNS DISEASES AND PAINS. | HEPTARES THERAPEUTICS LIMITED (GB) | 2018-04-19 | — | — | WO | disclosed |
| EP-0285000-B1 | CHROMOGENE COMPOUNDS, THEIR MANUFACTURE AND USE AS ENZYME SUBSTRATES | Roche Diagnostics GmbH (DE) | 1993-07-28 | — | — | EP | disclosed |
| US-5190862-A | Peptide modified compound | BOEHRINGER MANNHEIM GMBH (DE) | 1993-03-02 | — | — | US | disclosed |
| US-5108890-A | Diagnostic agents for determining peptide bond-cleaving enzymes; measuring light absorbed by liberated colored materials | BOEHRINGER MANNHEIM GMBH (DE) | 1992-04-28 | — | — | US | disclosed |
| EP-0285000-A2 | Chromogene compounds, their manufacture and use as enzyme substrates | Roche Diagnostics GmbH (DE) | 1988-10-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250368647-A1 | NITROGEN CONTAINING CONDENSED 2,3-DIHYDROQUINAZOLINONE COMPOUNDS AS NAV1.8 INHIBITORS | SCN8A, SCN2A, SCN5A | TXNRD1 4082/4885ALDH1A1 2933/4885GSR 3967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.